Skip to content
value.today

Corner Therapeutics, Inc.

🇺🇸 Watertown, Massachusetts, USAPharmaceuticalsFounded 2019
Total raised
$75 M
2 rounds on record
Latest round
$17 M
Sep 2025
First round on record
May 2023
Today
Private
No later event on record

Funding rounds

2 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Corner Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jun 2026$48 MIssued in a merger or acquisition$10 to $50 million

Corner Therapeutics, Inc.: Private sale, Jun 2026

Investors in this round

8 investors had bought by the notice of Nov 4, 2026: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$48 M of $48 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jonathan Kagan · Executive Officer
  • Michael Lyman · Executive Officer
  • Nick Seaver · Executive Officer, Director
  • Steven Altschuler · Executive Officer, Director
  • Alan Ezekowitz · Director
  • Fabian Tenenbaum · Director
  • Jeanne Cunicelli · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On a merger: “The offering consists solely of an equity financing consummated following the completion of a merger transaction. The securities included in this Form D were not issued in the merger.”

Signed by Steven Altschuler, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 4, 2026. Read the notice at the SEC.

equitySEC
Sep 2025$17 MNo. 2$10 to $50 million

Corner Therapeutics, Inc.: Raise no. 2, Sep 2025

Investors in this round

4 investors had bought by the notice of Oct 20, 2025: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$17 M of $17 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Cornforth · Executive Officer
  • Garrett Nichols · Executive Officer
  • Jonathan Kagan · Executive Officer, Director
  • Nick Seaver · Executive Officer, Director
  • Steven Altschuler · Executive Officer, Director
  • Alan Ezekowitz · Director
  • Andrew Bellinger · Director
  • Richard Malley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nick Seaver, President. Source: SEC Form D, newest notice filed Oct 20, 2025. Read the notice at the SEC.

debt, optionsSEC
May 2023$59 MNo. 1$50 to $250 million

Corner Therapeutics, Inc.: Raise no. 1, May 2023

Investors in this round

14 investors had bought by the notice of Aug 11, 2025: 14 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$59 M of $63 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrew Cornforth · Executive Officer
  • Jonathan Kagan · Executive Officer, Director
  • Nichols Garrett · Executive Officer
  • Nick Seaver · Executive Officer, Director
  • Steve Altschuler · Executive Officer, Director
  • Alan Ezekowitz · Director
  • Andrew Bellinger · Director
  • Richard Malley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nick Seaver, President. Source: SEC Form D and 2 amendments, newest notice filed Aug 11, 2025. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Corner Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2026).

    SEC Form D · Nov 2026

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Nov 2026

That is all the official record says: Corner Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Corner Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 14 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Corner Therapeutics, Inc.
NameRoleNamed in
Michael LymanExecutive officerNov 2026
Andrew CornforthExecutive officerOct 2025
Garrett NicholsExecutive officerOct 2025
Jonathan KaganExecutive officerOct 2025
Nick SeaverExecutive officerOct 2025
Steven AltschulerExecutive officerOct 2025
Nichols GarrettExecutive officerAug 2025
Steve AltschulerExecutive officerAug 2025
Jeffrey KarpExecutive officerApr 2024
Fabian TenenbaumDirectorNov 2026
Jeanne CunicelliDirectorNov 2026
Alan EzekowitzDirectorOct 2025
Andrew BellingerDirectorOct 2025
Jonathan KaganDirectorOct 2025
Nick SeaverDirectorOct 2025
Richard MalleyDirectorOct 2025
Steven AltschulerDirectorOct 2025
Steve AltschulerDirectorAug 2025